Cargando…
Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a devastating lung disease characterized by the progressive obstruction of the distal pulmonary arteries (PA). Structural and functional alteration of pulmonary artery smooth muscle cells (PASMC) and endothelial cells (PAEC) contributes to PA wall remodeling...
Autores principales: | Bisserier, Malik, Katz, Michael G., Bueno-Beti, Carlos, Brojakowska, Agnieszka, Zhang, Shihong, Gubara, Sarah, Kohlbrenner, Erik, Fazal, Shahood, Fargnoli, Anthony, Dorfmuller, Peter, Humbert, Marc, Hata, Akiko, Goukassian, David A., Sassi, Yassine, Hadri, Lahouaria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431626/ https://www.ncbi.nlm.nih.gov/pubmed/34502015 http://dx.doi.org/10.3390/ijms22179105 |
Ejemplares similares
-
Molecular and Genetic Profiling for Precision Medicines in Pulmonary Arterial Hypertension
por: Fazal, Shahood, et al.
Publicado: (2021) -
Lung-targeted SERCA2a Gene Therapy: From Discovery to Therapeutic Application in Bleomycin-Induced Pulmonary Fibrosis
por: Bisserier, Malik, et al.
Publicado: (2020) -
Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19
por: Hamouche, Walid, et al.
Publicado: (2021) -
Novel Insights into the Therapeutic Potential of Lung-Targeted Gene Transfer in the Most Common Respiratory Diseases
por: Bisserier, Malik, et al.
Publicado: (2022) -
Retrospective analysis of demographic factors in COVID-19 patients entering the Mount Sinai Health System
por: Eskandari, Abrisham, et al.
Publicado: (2021)